Navigation

Researchers at UCD

Nadezhda Glezeva

Post Doc Research Fellow Lvl I

School Of Medicine
Conway Institute
Belfield
Dublin 4

Tel:
Email: nadezhda.glezeva@ucd.ie

Biography

Dr. Nadezhda Glezeva is a molecular medicine scientist based in University College Dublin. She received her MSc degree from Charité University of Medicine (Berlin, Germany) and completed her PhD in UCD (Dublin, Ireland). She is a postdoctoral researcher in the Experimental & Clinical Cardiology group in UCD, and a cardiovascular translational research investigator for the Cardiology Department and the Chronic Cardiovascular Disease Management Group in St Vincent's University Hospital Group and the Heartbeat Trust charity in Dublin. Dr. Glezeva's research interests focus on chronic heart disease prevention and biomarker diagnostics. She is particularly interested in cardiovascular inflammation as a trigger for cardiac dysfunction and studies mechanisms that drive or interfere with inflammatory process to target pathological progression to heart failure in the healthy, at-risk populations. Additional research interests include drug re-purposing for orphan diseases and the pathophysiology of immune cells in conditions such as obesity, hypertension, and diabetes.

UCD Medicine Research Group - Cardiology and Cardiovascular Disease 

Professional

 

Associations

Association: European Society of Cardiology, Function/Role: Member
Association: Heart Failure Association of the ESC, Function/Role: Member
Association: Irish Cardiac Society, Function/Role: Member
     

Conference Contributions

McNamara, E; Tea Beng Loong, I; Glezeva, N; Watson, C; Baugh, J (2015) Investigating the role of leucine-rich alpha2-glycoprotein 1 in myocardial fibrosis. [Poster Presentation], 2nd Annual Meeting of Matrix Biology Ireland, UCD , 02-DEC-15 - 04-DEC-15.
Glezeva, N; Collier, P; O'Reilly, J; O'Connell, E; Tea, I; Ledwidge, M; McDonald, K; Baugh, J; Watson, C (2015) Tetranectin, a potential novel biomarker of heart failure, is expressed within the myocardium and associates with cardiac fibrosis. [Poster Presentation], European Society of Cardiology: 2nd World Congress on Acute Heart Failure, London , 29-AUG-15 - 02-SEP-15.
Watson, CJ; Gupta, S; O'Connell, E; Thum, S; Glezeva, N; Fendrich, J; Gallagher, J; Ledwidge, M; Thum, T (2015) MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. [Poster Presentation], European Society of Cardiology: 2nd World Congress on Acute Heart Failure, London , 29-AUG-15 - 02-SEP-15.
             

Other Activities

Project Management FETAC Level 6

Publications

     

Peer Reviewed Journals

Glezeva N, Gilmer JF;Watson CJ;Ledwidge M (2016) 'A Central Role for Monocyte-Platelet Interactions in Heart Failure'. Journal of Cardiovascular Pharmacology and Therapeutics, 21 (3):245-261. [DOI] [Details]
Glezeva N, Horgan S;Baugh JA (2015) 'Monocyte and macrophage subsets along the continuum to heart failure: Misguided heroes or targetable villains?'. Journal of Molecular and Cellular Cardiology, 89 (Pt B):136-145. [DOI] [Details]
Horgan SJ, Watson CJ;Glezeva N;Collier P;Neary R;Tea IJ;Corrigan N;Ledwidge M;McDonald K;Baugh JA (2015) 'Serum Amyloid P-Component Prevents Cardiac Remodeling in Hypertensive Heart Disease'. Journal of Cardiovascular Translational Research, 8 (9):554-566. [DOI] [Details]
Watson CJ, Horgan S;Neary R;Glezeva N;Tea I;Corrigan N;McDonald K;Ledwidge M;Baugh J (2015) 'Epigenetic Therapy for the Treatment of Hypertension-Induced Cardiac Hypertrophy and Fibrosis'. Journal of Cardiovascular Pharmacology and Therapeutics, . [DOI] [Details]
Glezeva N, Gallagher J;Ledwidge M;O'Donoghue J;McDonald K;Chipolombwe J;Watson C (2015) 'Heart failure in sub-Saharan Africa: review of the aetiology of heart failure and the role of point-of-care biomarker diagnostics'. Tropical Medicine and International Health, 20 (5):581-588. [DOI] [Details]
Watson CJ, Gupta SK;O'Connell E;Thum S;Glezeva N;Fendrich J;Gallagher J;Ledwidge M;Grote-Levi L;McDonald K;Thum T (2015) 'MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure'. European Journal of Heart Failure, 17 (4):405-415. [DOI] [Details]
Glezeva N, Voon V;Watson C;Horgan S;McDonald K;Ledwidge M;Baugh J (2015) 'Exaggerated inflammation and monocytosis associate with diastolic dysfunction in heart failure with preserved ejection fraction: evidence of M2 macrophage activation in disease pathogenesis'. Journal of Cardiac Failure, 21 (2):167-177. [DOI] [Details]
Horgan S, Watson C;Glezeva N;Baugh J (2014) 'Murine models of diastolic dysfunction and heart failure with preserved ejection fraction'. Journal of Cardiac Failure, 20 (12):984-995. [DOI] [Details]
Glezeva N, Baugh JA (2014) 'Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target'. Heart Failure Reviews, 19 (5):681-694. [DOI] [Details]
Watson CJ, Phelan D;Collier P;Horgan S;Glezeva N;Cooke G;Xu M;Ledwidge M;McDonald K;Baugh JA (2014) 'Extracellular matrix sub-types and mechanical stretch impact human cardiac fibroblast responses to transforming growth factor beta'. Connective Tissue Research, 55 (3):248-256. [DOI] [Details]
Glezeva N, Collier P;Voon V;Ledwidge M;McDonald K;Watson C;Baugh J (2013) 'Attenuation of monocyte chemotaxis--a novel anti-inflammatory mechanism of action for the cardio-protective hormone B-type natriuretic peptide'. Journal of Cardiovascular Translational Research, 6 (4):545-557. [DOI] [Details]
                           

Abstract

Glezeva, N,Voon, V,Watson, C,Ledwidge, M,McDonald, K,Baugh, J (2012) Patients with Hypertension and Heart Failure with Preserved Ejection Fraction Present with Elevated Inflammatory and Alternative Monocyte/Macrophage-Apecific Markers in their Peripheral Circulation. Abstract [Details]
Glezeva, N,Collier, P,Watson, C,Ledwidge, M,McDonald, K,Baugh, J (2010) ATTENUATION OF MONOCYTE CHEMOTAXIS-A NOVEL ANTI-INFLAMMATORY MECHANISM OF ACTION FOR THE CARDIOPROTECTIVE HORMONE B-TYPE NATRIURETIC PEPTIDE. Abstract [Details]
                                                               

Research

Research Interests

My research interests are in cardiovascular disease prevention and therapy with particular focus on cardiovascular inflammation as a trigger for cardiac dysfunction. I am studying mechanisms that drive or interfere with the inflammatory process to target pathological progression to heart failure in the healthy, at-risk populations. Additional research interests include drug re-purposing for orphan diseases and the pathophysiology of immune cells in conditions such as obesity, hypertension, and diabetes.

The projects I am currently involved in are:

Project 1: Biomarker research to establish and validate a novel multi-marker panel for Heart Failure. A collaborative project with Enterprise Ireland and St. Vincent's university hospital involving large-scale clinical sample procurement and management.

2. Project 2: Cardiovascular inflammation as a trigger for cardiac dysfunction. Project includes studying mechanisms that drive or interfere with inflammatory processes to target pathological progression to heart failure in healthy, at-risk populations. Additionally, it includes drug re-purposing for orphan diseases and the pathophysiology of inflammatory cells (leukocytes and platelets) in conditions such as obesity, hypertension, diabetes, and heart failure. This is a collaborative project between University College Dublin, Trinity College Dublin, St. Vincent's Hospital and the Heart Beat charity. 

3. Project 3: The gHealth Research project (http://ghealthresearch.org) is centred in University College Dublin, and is a collaboration between industry and universities in Ireland, UK, USA, Malawi, and Uganda. The multi-disciplinary team is focused on low and middle income countries where we are developing new strategies for diagnosis, treatment and management of disease. To date these strategies include biomarker & therapeutic research, mHealth and health care system reform.

4. Project 4: Epigenetic therapy for the treatment of hypertrophic cardiomyopathies. An Enterprise Ireland funded project that is aimed at developing a commercial platform for a second medicinal use of the DNA methylation inhibitor drug 5-azacytidine (Vidaza, FDA approved for treatment of MDS and AML) that we believe has novel anti-hypertrophic effects and will be useful in the treatment of cardiac diseases.  

     

Collaborators

Internal Collaborators

Dr John Baugh (UCD)
Dr Chris Watson (UCD, Queen's University Belfast)
Dr Mark Ledwidge (UCD, SVUH, The Heartbeat Trust)
Prof Ken McDonald (UCD, SVUH, The Heartbeat Trust)

 

External Collaborators

Dr John Gilmer (TCD)
Dr Carlos Medina (UCD) 
Prof Thomas Thum (Imperial College London, Hannover Medical School) 
Prof Stephane Heymans (Maastricht University)